达能首席执行官盛睿安表示："科学与创新始终是达能使命的核心，我们致力于通过食品为尽可能多的 人带来健康。达能OneBiome实验室的启用是'振新达能'战略新篇章的里程碑。它将进一步夯实达能在肠 道微生态系统这一科研领域的能力，并持续巩固达能在科学驱动健康创新方面的领导地位。" 9月29日，位于巴黎萨克雷的达能OneBiome实验室正式启用，标志着达能在以科学为基础的创新和肠道 健康研究领域迈出关键一步。该实验室将成为达能在肠道微生态、营养及数字健康领域的全球研发枢 纽，进一步加强其在塑造食品与健康未来方面的先锋地位。 OneBiome实验室创立于新加坡，设立初期专注于生命早期健康研究。巴黎萨克雷OneBiome实验室的启 用将借助达能百年来积累的专业知识、科学数据、临床研究以及对消费者需求的深刻洞察，加速肠道微 生态及其对整体健康影响的研究进程。该实验室将通过先进的微生物学、人工智能与数据科学，推动精 准营养解决方案的开发，强化达能在肠道健康与数字科学领域的领导力，更好地服务全球消费者与患 者。 近年来，肠道微生态科学取得飞跃发展，其在整体健康与福祉中的关键作用日益受到关注。尽管科学界 与公众对肠道健康的兴趣 ...

本报讯(记者梁傲男)9月29日，达能位于巴黎萨克雷的达能OneBiome实验室正式启用，标志着达能在以 科学为基础的创新和肠道健康研究领域迈出关键一步。该实验室将成为达能在肠道微生态、营养及数字 健康领域的全球研发枢纽，进一步加强其在塑造食品与健康未来方面的先锋地位。 在中国，达能也始终致力于通过肠道微生态科学赋能消费者健康，提供覆盖全生命周期的营养解决方 案。例如，在生命早期营养领域，含有Syneo特定益生元与益生菌组合的爱他美领熠系列产品通过塑造 宝宝健康的肠道微生态，支持长效自护。在成人与中老年营养领域，一项名为"玄武"的临床研究在近日 发表了临床结果，显示达能独家研发的共生元青常力益生组合能够通过靶向干预肠道微生态"年轻化"， 为中老年人群带来显著健康益处。 达能中国、北亚及大洋洲总裁谢伟博表示："在达能，我们坚信科学和营养的力量，并始终坚持将全球 科研与本地洞察相结合，为当地消费者带来健康价值。中国拥有独特的数字生态，使我们能够把科研转 化为真正为患者、消费者与医疗专业人士创造价值的解决方案。中国的速度与规模也意味着，我们可以 快速创新、获取反馈并持续迭代——扎根中国，服务中国，惠及全球。" 达能首 ...

Core Viewpoint - The company has demonstrated steady growth in the first half of 2025 despite challenges in the pharmaceutical industry, achieving a revenue of 1.949 billion yuan and a net profit of 343 million yuan, reflecting a year-on-year increase of 1.11% and 10.04% respectively [4]. Company Overview - Total assets at the end of the reporting period reached approximately 5.633 billion yuan, an increase of 8.70% compared to the previous year [2]. - The net assets attributable to shareholders increased by 1.86% to approximately 4.142 billion yuan [2]. - The company reported a basic earnings per share of 0.80 yuan, up 11.11% from the previous year [2]. Financial Performance - The total revenue for the first half of 2025 was 1.949 billion yuan, a slight increase of 1.11% from 1.928 billion yuan in the same period last year [2][4]. - The total profit amounted to 420 million yuan, representing an 8.36% increase from 388 million yuan year-on-year [2]. - The net profit attributable to shareholders was 343 million yuan, up 10.04% from 312 million yuan in the previous year [2][4]. Market Strategy and Operations - The company has focused on enhancing communication and cooperation with retail channels, leading to improved efficiency in channel collaboration [5]. - The retail terminal has seen significant growth in key chains and product categories, with a notable increase in the output of terminal products [5]. - The company has expanded its product line in the anorectal health sector, launching new products and enhancing user experience [5][6]. Product Development - The company has successfully launched functional probiotics and is actively developing projects related to intestinal and anorectal microecology [6]. - The ophthalmic product line has been enriched with the registration of sodium hyaluronate eye drops, and the company is advancing the production and market launch [6]. - The company is also expanding its presence in the beauty and skincare market, with significant growth in its beauty product line [6]. Challenges and Adaptations - The pharmaceutical industry is facing structural adjustments, prompting the company to optimize its store structure and enhance the health promotion functions of pharmacies [7]. - The company is exploring online business expansion and optimizing product structure to improve profitability [7]. - The company has initiated health-related public welfare activities to enhance brand visibility and consumer engagement [7].

Core Viewpoint - Breast milk is the best nutrition for infants, providing a balanced diet and unique self-protective properties, which are essential for their growth and development [1] Group 1: Importance of Breast Milk Components - Breast milk contains key components such as A2 protein, HMO (human milk oligosaccharides), and probiotics that help establish a strong self-protective system for infants [1][2] - A2 protein is more digestible than A1 protein, reducing digestive discomfort and inflammation, while also increasing the concentration of GSH (glutathione) by up to 4 times, enhancing antioxidant capacity [2] - HMO acts as a defense mechanism in the gut, promoting beneficial bacteria growth and enhancing the infant's ability to resist infections [3][4] Group 2: Role of Gut Microbiota - A balanced gut microbiota is crucial for infants, as an imbalance can lead to issues like diarrhea, constipation, and weakened immunity [3] - Probiotics, particularly bifidobacteria, are essential for gut health, helping to suppress harmful bacteria and maintain a balanced microbiome [4] Group 3: Guidelines for Choosing Infant Formula - Parents are advised to focus on three key elements when selecting infant formula: A2 protein, HMO, and probiotics, forming the "self-protective golden triangle" [5] - It is recommended to prioritize A2 protein formulas, check for the types and amounts of HMO, and ensure sufficient levels of probiotics, especially bifidobacteria [5] - Regular consultation with pediatricians or nutrition experts is suggested to adjust formula choices based on the infant's growth and nutritional needs [6]

Core Insights - Obesity is one of the top ten chronic diseases globally, with projections indicating that by 2030, the overweight and obesity rate among adults in China will reach 70.5%, and among children, it will reach 31.8% [1] - Traditional weight loss methods often lead to rebound effects and poor experiences, highlighting the need for more scientific and instinctive solutions [1] - Akk11, derived from the gut microbiota of healthy infants in pollution-free highland areas, represents a new approach to weight management by balancing metabolism and promoting gentle weight loss [1] Company and Product Development - Microbiome company has established an industry-leading fully anaerobic automated production line for Akk11, utilizing advanced technologies such as fully automated anaerobic fermentation systems and high-precision centrifugation [2] - Akk11's specifications include 600 billion AFU/gram for live bacteria and 10 trillion TFU/gram for inactivated bacteria, with an annual production capacity exceeding 200 tons, meeting market demand [2] - Akk11 is expected to receive GRAS safety certification in the United States in 2024 [2][5] Clinical Research and Efficacy - Clinical studies indicate that Akk11 effectively improves body fat, metabolic levels, and emotional health, functioning through appetite control, metabolic activation, and enhanced energy expenditure [1] - Akk11 also regulates oxidative stress, improves sleep and emotional health, creating a positive feedback loop between metabolic improvement and mental well-being [1] Market Potential and Future Outlook - Akk11 has garnered global attention in the health industry, particularly at the 2025 Natural Products Expo West in the United States, showcasing its potential beyond weight loss, including benefits for blood pressure stability and bone health [6] - The product has multiple patents and clinical research supporting its effects on blood lipid regulation, liver protection, and anti-aging, indicating a broad application prospect [6] - The company aims to continue focusing on promoting human health and environmental sustainability through high-quality microbiota [7]

Core Insights - The forum on microecological medicine and fecal microbiota transplantation was held in Yantai, highlighting advancements in gut microbiome research and clinical applications [1][3][13] - The establishment of the Shandong Provincial Gut Microecological Diagnosis and Treatment Center in Yantai marks a significant step in integrating clinical and research efforts in this field [3][13] Group 1: Forum Highlights - Experts discussed the latest developments in gut microbiome medicine and the standardization of fecal microbiota transplantation techniques [1][3] - The forum featured prominent figures from various medical institutions, emphasizing the collaborative nature of the event [1][3][5] Group 2: Institutional Developments - The Yantai Yuhuangding Hospital has established a clinical and research system for gut microbiome, becoming a key player in the region [3][5] - A cooperation agreement was signed between Yantai Yuhuangding Hospital and the Shanghai National Engineering Research Center for Biochips to enhance research and clinical practices in gut microbiome and fecal transplantation [13] Group 3: Future Directions - The hospital aims to collaborate with universities, enterprises, and medical institutions to foster innovation in the field of gut microbiome medicine [3][9] - There is a focus on expanding research into the relationship between gut microbiome and overall health, including mental health and childhood development [9][15]